Correlation Between Gut Microbiota Characteristics and Immunotherapy Efficacy in Patients with Advanced Microsatellite Stable Gastrointestinal Tumors
10.3971/j.issn.1000-8578.2026.26.0139
- VernacularTitle:肠道微生态特征与晚期MSS型消化道肿瘤免疫治疗疗效的相关性
- Author:
Yanfei LIU
1
;
Ting GE
1
;
Xi XIE
1
;
Yujie ZHOU
1
;
Min CHENG
1
;
Yan ZHANG
1
;
Guang FU
2
;
Hongyan JIN
1
Author Information
1. Oncology Department of Wuhan Puren Hospital, Wuhan 430081, China.
2. Second Gastrointestinal Surgery Ward of Wuhan Puren Hospital, Wuhan 430081, China.
- Publication Type:CLINICALRESEARCH
- Keywords:
Gastrointestinal tumor;
Intestinal microecology;
Immunotherapy;
Microsatellite stable;
Disease control rate
- From:
Cancer Research on Prevention and Treatment
2026;53(8):600-608
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the correlation between gut microbiota characteristics and immunotherapy efficacy in patients with advanced microsatellite stable (MSS) advanced gastrointestinal tumors. Methods Thirty patients with advanced MSS gastrointestinal tumors, including fourteen cases of gastric cancer and sixteen cases of colorectal cancer, who were admitted from November 1, 2022, to July 31, 2025 were enrolled. All patients underwent gut microbiota testing and received corresponding interventions on the basis of the results, followed by treatment with antiangiogenic agents combined with immunotherapy. Some patients additionally received probiotics or fecal microbiota transplantation. The primary endpoints were disease control rate (DCR) and objective response rate (ORR). The secondary endpoints were progression-free survival (PFS) and overall survival (OS). Univariate and multivariate Cox regression analyses were used to assess potential prognostic factors. Results Among the thirty patients, no complete response was observed. Two cases of partial response (PR), twelve cases of stable disease, and sixteen cases of progressive disease were recorded. The ORR was 6.7%, and the DCR was 46.7%. The median PFS was 6.4 months, and the median OS was 8.3 months. Both PR patients were classified as having a medium risk of gut microbiota dysbiosis and exhibited a Bacteroides-dominated enterotype. Multivariate analysis indicated that tumor type, liver metastasis, and bone metastasis were potential prognostic factors for PFS and OS. Conclusion Patients with a medium risk of gut dysbiosis may exhibit a relatively favorable response to immunotherapy, suggesting that gut microbiota status could serve as a potential biomarker for predicting treatment efficacy in advanced MSS gastrointestinal tumors.
